Cytomegalovirus “Blips” and Rates of Progression to Clinically Significant CMV in Cardiothoracic Transplant Recipients
Transplant Infectious Disease · 2026-07 · 28 (4)
DOI: 10.1111/tid.70206 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, online erschienen am 19.03.2026. Verfasst von Alison M Samsel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Heart Transplantation, Cytomegalovirus, Lung Transplantation. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Guidelines suggest using a highly sensitive, quantitative nucleic acid test (QNAT) for CMV detection; however, there is no standardized threshold to guide preemptive therapy or initiation of CMV treatment. This study sought to characterize the incidence, time course, and management of CMV blips as well as the rate of progression to clinically significant CMV infection (CS‐CMVi) following a blip in cardiothoracic transplant recipients.
Methods
This is a single‐center, retrospective study of heart and lung transplant recipients from January 2018 to August 2024. A CMV blip was defined as the first positive, detectable, and unquantifiable CMV‐QNAT. CS‐CMVi was defined as either viral load > 1000 IU/mL or initiation of treatment following a blip. Outcomes were assessed within 1 year of transplant.
Results
Of the 196 patients included in the study, 58 patients (29.6%) had a CMV blip. A majority of patients (62.1%) were receiving CMV prophylaxis at the time of blip. The median time from transplant to CMV blip was 77.5 days and median time to CS‐CMVi, from blip, was 30 days. In the CMV high‐risk group (D+/R−), 71.4% (10/14) developed CS‐CMVi, compared with 21.4% (9/42) in the moderate risk group (R+) ( p = 0.001).
Conclusion
In the first year following cardiothoracic transplantation, CMV blips are common occurrences. Patients at high‐risk for CMV were more likely to progress to CS‐CMVi than moderate risk patients. In the high‐risk population, this increased rate of progression gives further evidence that a CMV blip is a risk for the progression of CS‐CMVi in the absence of treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, Maryland, USA.
- Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.
- Division of Thoracic Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Pathology, Division of Medical Microbiology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
- Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Sara Strout, Robin K Avery, Errol L Bush, M Veronica Dioverti, Paul J Scheel, Pali D Shah, Priya Umapathi, Brian K Lindner
Zitieren
APA
Samsel, A. M., Strout, S., Avery, R. K., Bush, E. L., Dioverti, M. V., Mostafa, H. H., Scheel, P. J., Shah, P. D., Umapathi, P., & Lindner, B. K. (2026). Cytomegalovirus “Blips” and Rates of Progression to Clinically Significant CMV in Cardiothoracic Transplant Recipients. Transplant Infectious Disease, 28(4). https://doi.org/10.1111/tid.70206
Vancouver
Samsel AM, Strout S, Avery RK, Bush EL, Dioverti MV, Mostafa HH, et al. Cytomegalovirus “Blips” and Rates of Progression to Clinically Significant CMV in Cardiothoracic Transplant Recipients. Transplant Infectious Disease. 2026;28(4). doi:10.1111/tid.70206
BibTeX
@article{Samsel2026,
author = {Samsel, Alison M and Strout, Sara and Avery, Robin K and Bush, Errol L and Dioverti, M Veronica and Mostafa, Heba H and Scheel, Paul J and Shah, Pali D and Umapathi, Priya and Lindner, Brian K},
title = {Cytomegalovirus “Blips” and Rates of Progression to Clinically Significant CMV in Cardiothoracic Transplant Recipients},
journal = {Transplant Infectious Disease},
year = {2026},
volume = {28},
number = {4},
doi = {10.1111/tid.70206}
}
EUVIMED